MCO
AUTL

MAK Capital One’s Autolus Therapeutics AUTL Stock Holding History

MAK Capital One’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$53.8M Hold
33,621,487
– – 7.54% 6
2026
Q1 		$46.4M Buy
33,621,487
+3,616,144
+12% +$5.49M 6.84% 6
2025
Q4 		$59.7M Buy
30,005,343
+3,987,727
+15% +$6.13M 6.57% 6
2025
Q3 		$42.4M Buy
26,017,616
+9,062,518
+53% +$17.7M 6.52% 5
2025
Q2 		$38.7M Buy
+16,955,098
New +$28M 5.54% 6

Other funds holding AUTL

Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

MAK Capital One's AUTL Position: Q2 2026 in Review

MAK Capital One held its Autolus Therapeutics (AUTL) position steady in Q2 2026 at 33,621,487 shares worth $53.8M. The position accounts for 7.54% of the portfolio, ranked #6.

MAK Capital One first reported a position in AUTL in Q2 2025 and has held it in 5 quarters since. The position peaked at $59.7M in Q4 2025. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • MAK Capital One held 33,621,487 shares of Autolus Therapeutics worth $53.8M as of Q2 2026.
  • MAK Capital One left its Autolus Therapeutics share count unchanged in Q2 2026.
  • Autolus Therapeutics made up 7.54% of MAK Capital One's portfolio in Q2 2026, its #6 holding.
  • MAK Capital One first reported a position in Autolus Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • MAK Capital One's Autolus Therapeutics position peaked at $59.7M in Q4 2025.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on MAK Capital One's 13F filing for Q2 2026, filed 14 Aug 2026.